SCHEDULE 13G/A: ARK Investment Management Discloses Passive 4.70% Stake in Repare Therapeutics
Beneficial Ownership Disclosure
ARK Investment Management LLC has disclosed a 4.70% passive ownership stake in Repare Therapeutics Inc. as of December 31, 2024, according to a recent Schedule 13G filing.
Summary
- ARK Investment Management LLC reported beneficial ownership of 1,999,996 common shares of Repare Therapeutics Inc.
- This stake represents 4.70% of the company's common shares outstanding.
- The filing, an Amendment No. 3 to Schedule 13G, was dated February 14, 2025, with the event date being December 31, 2024.
- ARK Investment Management LLC holds sole voting power and sole dispositive power over all 1,999,996 reported shares.
- The shares were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing the control of Repare Therapeutics Inc.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing (Schedule 13G) disclosing a passive ownership stake. It contains factual information about shareholding and does not present inherently positive or negative news about the company's operations or financial performance, thus maintaining a neutral sentiment.
Positives
- ARK Investment Management LLC, a prominent investment adviser, maintains a significant stake in Repare Therapeutics Inc., which may be viewed as a vote of confidence.
- The stake is classified as passive, indicating no intent to influence or change control of the issuer, which suggests stability in the ownership structure.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- "To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Statement from Kellen Carter, Chief Compliance Officer of ARK Investment Management LLC)
Industry Context
This filing is a routine disclosure of an institutional investor's passive ownership stake in a biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape beyond the fact that a notable investment firm holds a position in a company within the sector.
Comparison to Industry Standards
- NA
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership in the company, confirming a passive investment approach by ARK Investment Management LLC.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (end of reporting period for ownership calculation) |
| 02/14/2025 | Date of filing/signature of the Schedule 13G Amendment No. 3 |
Keywords
Repare Therapeutics, ARK Investment Management, Schedule 13G, beneficial ownership, common shares, investment adviser, passive stake, biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.